Literature DB >> 6631599

Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis.

I K Hewitt, C Stefanidis, B J Reilly, S W Kooh, J W Balfe.   

Abstract

Fifteen children undergoing continuous ambulatory peritoneal dialysis for 0.3 to 2.4 years were evaluated longitudinally for renal osteodystrophy. Immunoreactive parathyroid hormone, 25-OHD, total and ionized calcium, inorganic phosphate, and alkaline phosphatase levels were measured regularly. Skeletal radiographic studies were performed at the onset and conclusion of CAPD and at six-month intervals during therapy. All children received 1,25(OH)2D3 and aluminum hydroxide, and nine received supplemental calcium. Plasma 25-OHD concentrations were normal to elevated, and calcium increased steadily to high normal levels despite a trend to persistent hyperphosphatemia. The increased calcium levels suppressed parathyroid hormone overactivity in only one patient. At the onset of CAPD, nine patients had hyperparathyroid bone disease seen radiographically, three of whom also had rachitic lesions. At the end of CAPD, the hyperparathyroid lesions had improved in four patients, completely resolved in three, and deteriorated in two. Rachitic lesions had completely healed in two patients and improved in the third. However, among the six children without radiographically evident lesions at onset of CAPD, hyperparathyroid bone lesions developed in two and rachitic lesions in two others during CAPD. Although CAPD and appropriate therapy benefited most patients with renal osteodystrophy, the benefits were not uniform, and bone lesions deteriorated in some.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6631599     DOI: 10.1016/s0022-3476(83)80466-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  1 in total

Review 1.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.